Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | OPTHEA LTD SPONSORED ADR OPTEY | BAKER BROS. ADVISORS LP | 31,627,844 6.800% | 5,200,323 (+19.68%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | KALA BIO, Inc. KALA | BAKER BROS. ADVISORS LP | 180,913 9.990% | 180,913 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | 2seventy bio, Inc. TSVT | BAKER BROS. ADVISORS LP | 2,062,744 5.400% | 2,062,744 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Verastem, Inc. VSTM | BAKER BROS. ADVISORS LP | 2,249,075 13.500% | 458,106 (+25.58%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | BAKER BROS. ADVISORS LP | 19,184,794 9.950% | 720,050 (+3.90%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Zymeworks Inc. ZYME | BAKER BROS. ADVISORS LP | 3,814,196 5.900% | 3,814,196 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Cerus Corporation CERS | BAKER BROS. ADVISORS LP | 16,087,422 9.100% | 2,354,363 (+17.14%) | Filing History |
| 2023-02-14 4:00 pm Sale | 2022-12-31 | 13G | Merus N.V. MRUS | BAKER BROS. ADVISORS LP | 0 0.000% | -2,037,469 (Position Closed) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Mereo BioPharma Group plc MREO | BAKER BROS. ADVISORS LP | 69,359,359 9.990% | 4,441,758 (+6.84%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Achilles Therapeutics plc ACHL | BAKER BROS. ADVISORS LP | 4,207,733 9.900% | 168,253 (+4.17%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 255,361 9.900% | 53,581 (+26.55%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Ascendis Pharma A/S ASND | BAKER BROS. ADVISORS LP | 4,954,855 8.700% | 413,251 (+9.10%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | BAKER BROS. ADVISORS LP | 56,482 8.000% | 4,145 (+7.92%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Biomea Fusion, Inc. BMEA | BAKER BROS. ADVISORS LP | 2,104,559 7.200% | 2,104,559 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Cabaletta Bio, Inc. CABA | BAKER BROS. ADVISORS LP | 1,344,000 5.200% | 1,344,000 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT | BAKER BROS. ADVISORS LP | 2,492,118 7.000% | 2,492,118 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Immatics N.V. IMTX | BAKER BROS. ADVISORS LP | 5,187,081 6.800% | 763,350 (+17.26%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Replimune Group, Inc. REPL | BAKER BROS. ADVISORS LP | 5,768,227 9.990% | 5,768,227 (New Position) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | BAKER BROS. ADVISORS LP | 6,354,608 11.300% | 291,906 (+4.81%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Inozyme Pharma, Inc. INZY | BAKER BROS. ADVISORS LP | 2,168,000 5.100% | 2,168,000 (New Position) | Filing History |